Published in State and Local Health Law Weekly, October 25th, 2007
"Given his strong track record in all aspects pharmaceutical commercialization, we are thrilled to welcome Bill to our management team," commented Steve Orndorff, Ph.D., president and CEO. "We are confident that his strong track record combined with Ketasyn's excellent safety and efficacy will allow Accera to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of State and Local Health Law Weekly